TD Asset Management’s Entrada Therapeutics TRDA Stock Holding History

TD Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$676K	Buy	53,588 +15,800	+42%	+$181K	﹤0.01%	1144
2025 Q4	$388K	Hold	37,788	–	–	﹤0.01%	1190
2025 Q3	$219K	Sell	37,788 -10,000	-21%	-$58.5K	﹤0.01%	1217
2025 Q2	$321K	Hold	47,788	–	–	﹤0.01%	1157
2025 Q1	$432K	Hold	47,788	–	–	﹤0.01%	1158
2024 Q4	$826K	Hold	47,788	–	–	﹤0.01%	1133
2024 Q3	$786K	Sell	47,788 -23,520	-33%	-$371K	﹤0.01%	1237
2024 Q2	$1.02M	Hold	71,308	–	–	﹤0.01%	1156
2024 Q1	$1.01M	Sell	71,308 -47,946	-40%	-$678K	﹤0.01%	1162
2023 Q4	$1.8M	Hold	119,254	–	–	﹤0.01%	1039
2023 Q3	$1.88M	Buy	119,254 +59,627	+100%	+$939K	﹤0.01%	973
2023 Q2	$903K	Hold	59,627	–	–	﹤0.01%	1152
2023 Q1	$865K	Hold	59,627	–	–	﹤0.01%	1161
2022 Q4	$806K	Buy	59,627 +131	+0.2%	+$2.3K	﹤0.01%	1185
2022 Q3	$925K	Buy	59,496 +1,821	+3%	+$23.1K	﹤0.01%	1195
2022 Q2	$702K	Hold	57,675	–	–	﹤0.01%	1240
2022 Q1	$542K	Hold	57,675	–	–	﹤0.01%	1336
2021 Q4	$987K	Buy	+57,675	New	+$1.4M	﹤0.01%	1275

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TD Asset Management's TRDA Position: Q1 2026 in Review

TD Asset Management increased its Entrada Therapeutics (TRDA) stake by 42% in Q1 2026, buying an estimated $181K and bringing the position to 53,588 shares worth $676K. The position accounts for ﹤0.01% of the portfolio, ranked #1144.

TD Asset Management first reported a position in TRDA in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.88M in Q3 2023. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

TD Asset Management held 53,588 shares of Entrada Therapeutics worth $676K as of Q1 2026.
TD Asset Management bought 15,800 Entrada Therapeutics shares in Q1 2026, an estimated $181K.
Entrada Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q1 2026, its #1144 holding.
TD Asset Management first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 18 quarters since.
TD Asset Management's Entrada Therapeutics position peaked at $1.88M in Q3 2023.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.